Merck (MRK) said Tuesday that Health Canada has granted approval for Keytruda as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non-small cell lung carcinoma.
The approval is for Keytruda to be administered in combination with platinum-containing chemotherapy as neoadjuvant treatment and as a monotherapy for adjuvant treatment after surgery, Merck said.
The company said the approval was based on the results of a phase 3 trial, where Keytruda demonstrated "statistically significant" results for the primary endpoints of event-free survival and overall survival.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.